Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Roundtable Top Picks of the Week
- The Mega-Rally Rolls On
- RTI: Prediction Contest: S&P 500 on Dec. 31st
- Industry Rank Analysis: Shifting Into Overdrive
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Options Strategies & the Zacks Rank
- AWS 5/20: The Fed In Focus This Week
- PFP 5/20: Will We Touch 1700?
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/20/2013
| Company Name | Symbol | %Change |
|---|---|---|
| ORBOTECH LTD | ORBK | 10.86% |
| SONIC FOUNDR | SOFO | 9.45% |
| VIPSHOP HOLD | VIPS | 9.20% |
| RENEWABLE EN | REGI | 8.98% |
| EAGLE BULK S | EGLE | 7.84% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Allos Therapeutics ( ) suffered a loss of 11 cents in the first quarter of 2012 as opposed to a loss of 14 cents per share incurred in the year-ago quarter. An increase in total revenue coupled with lower costs led to the narrower loss in the first quarter of 2012. The Zacks Consensus Estimate hinted at a loss of 5 cents per share. The results were announced through a filing with the Securities and Exchange Commission.
Quarterly Results
Total revenue in the reported quarter climbed 4.3% to $11.3 million. Net product sales at Allos fell 10.1% to $9.8 million. Allos derives its product revenues from selling Folotyn. Folotyn (pralatrexate) is marketed for the treatment of patients suffering from relapsed or refractory peripheral T-cell lymphoma (PTCL).
Despite the fall in Folotyn sales, revenues increased year over year due to the presence of $1.6 million as license and other revenues pertaining to Allos’ deal with Mundipharma (inked in May 2011) for the co-development of Folotyn. The Zacks Consensus Estimate was $14 million.
Both selling, general and administrative (SG&A) and research & development (R&D) expenses were on the downswing during the quarter, declining 12.5% and 29.3%, respectively, primarily due to the company’s prudent cost management strategy.
Allos to be taken over by Spectrum Pharma
On April 4, 2012, Allos announced that it will be acquired by Spectrum Pharmaceuticals ( SPPI - Snapshot Report ) . Per the terms of the deal, Spectrum Pharma agreed to acquire Allos for $1.82 per share in cash, in addition to one contingent value right (CVR).
Spectrum Pharma has initiated a tender offer to buy the entire outstanding shares of Allos for the above mentioned purchase price. At the time of announcing the deal, expected to close shortly, the companies stated that the CVR makes each Allos shareholder eligible to receive a further 11 cents per share in cash depending on the conditional European approval and achievement of certain milestones of Folotyn.
At the time of announcing the deal, management at Spectrum Pharma had stated that the acquisition, which has been cleared by the Boards of both companies, is expected to boost Spectrum Pharma’s earnings in the final quarter of 2012.
Our Recommendation
Currently, we have an Outperform Recommendation on the stock. The company carries a Zacks #2 Rank (short-term Buy rating).
Read the full reports :
Snapshot Report on SPPI